Rankings
▼
Calendar
RIGL Q3 2023 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RIGL
Rigel Pharmaceuticals, Inc.
$541M
Q3 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$28M
+25.5% YoY
Gross Profit
$27M
95.5% margin
Operating Income
-$4M
-15.9% margin
Net Income
-$6M
-20.2% margin
EPS (Diluted)
$-0.33
QoQ Revenue Growth
+4.6%
Cash Flow
Operating Cash Flow
-$1M
Free Cash Flow
-$1M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$115M
Total Liabilities
$147M
Stockholders' Equity
-$32M
Cash & Equivalents
$45M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$28M
$22M
+25.5%
Gross Profit
$27M
$22M
+21.2%
Operating Income
-$4M
-$18M
+75.7%
Net Income
-$6M
-$19M
+70.1%
Revenue Segments
Gross product sales
$39M
68%
Product sales, net
$27M
48%
Contract revenues from collaborations
$1M
2%
Government contract
$1M
2%
Development milestones
$75,000
0%
Discounts and allowances
-$11M
-20%
← FY 2023
All Quarters
Q4 2023 →